Last updated on August 2017

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia Alzheimer's Disease and Healthy Volunteers

Brief description of study

Single site, parallel-group, double-blind trial of low or high dose of BI 409306 to evaluate the ocular and systemic safety and pharmacokinetics during 14 day treatment period in patients with schizophrenia, Alzheimer's disease, or age comparable healthy volunteers.

Clinical Study Identifier: NCT02392468

Contact Investigators or Research Sites near you

Start Over

Boehringer Ingelheim Call Center

Memory Enhancement Center of America, Inc.
Eatontown, NJ United States
  Connect »